Use AP Pharma Inc management performance within your existing portfolios mixed with equities fromn OTC Bulletin Board to protect against small markets fluctuations as well as to determine Stock diversification method that is right for you. Build PortfolioAP Pharma Management EffectivenessThe company has return on total asset (ROA) of (39.5) % which means that it has lost $39.5 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (72.31) % meaning that it created substantial loss on money invested by shareholders. AP Pharma InsidersAP Pharma Inc WorkforceAP Pharma Inc is rated below average in number of employees category among related companies. The total workforce of Drug Manufacturers - Major industry is presently estimated at about 759,493. AP Pharma adds roughly 32.0 in number of employees claiming only tiny portion of equities under Drug Manufacturers - Major industry.
|
John Whelan CEOPresident CEO, CFO, Director Mr. John B. Whelan is President, Chief Executive Officer, Chief Financial Officer, Director of AP Pharma Inc. He was appointed as President, Chief Executive Officer and Director of the Company effective April 24, 2011... | Paul Goddard ChairmanIndependent Chairman of the Board Dr. Paul Goddard, Ph.D. has served as Independent Chairman of the Board of AP Pharma Inc., since November 2000... |
Tenure AnalysisAP Pharma employes about 32 people. The company is managed by 15 executives with total tenure of roughly 25 years, averanging almost 1.0 years of service per executive having 2.0 employee per reported executive.Return on AP Pharma Manpower| Revenue Per Employee | 7.8 K | | Revenue Per Executive | 16.7 K | | Net Loss Per Employee | 763.4 K | | Net Loss Per Executive | 1.6 M | | Working Capital Per Employee | 1.6 M | | Working Capital Per Executive | 3.3 M |
AP Pharma Earnings Per ShareAccording to company disclosure AP Pharma Inc has Earnings Per Share of -0.1 times. This is 105.32% lower than that of Healthcare sector, and 101.16% lower than that of Drug Manufacturers - Major industry, The Earnings Per Share for all stocks is 105.46% higher than the company.
|
0.36%
Equity Search
Advanced Search
Market Screener
Adviser Directory
Suggest Portfolio
Backtest Watchlist
Analyze Correlations
View Transactions
Check Volatility
Import Equities
